Showing results (81-90 of 107) with videos related to
Sort By:
Pageof 11
British Journal of Pharmacology|May 31, 2017
A pharmacokinetic-pharmacodynamic model predicting tumour growth inhibition after intermittent administration with the mTOR kinase inhibitor AZD8055James W T Yates, Sarah V Holt, Armelle Logie, et al.The British Journal of Radiology|July 1, 1990
Glutathione and cysteine levels in human tumour biopsiesM Guichard, F Lespinasse, R Estelin, et al.Artificial Cells, Blood Substitutes, and Immobilization Biotechnology|January 1, 1994
Tumor oxygenation after 1) carbogen and/or perflubron emulsion administration in tumor xenografts 2) carbogen administration in patientsM Guichard, E Lartigau, L Martin, et al.Biochemical Pharmacology|December 20, 2005
Anti-tumour activity in non-small cell lung cancer models and toxicity profiles for novel ruthenium(II) based organo-metallic compoundsS M Guichard, R Else, E Reid, et al.Biochemical Society Transactions|March 25, 2011
Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055Gayle Marshall, Zoe Howard, Jonathan Dry, et al.Journal of Pediatric Hematology/Oncology|October 7, 2006
Pilot study to evaluate MYCN expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCRLars M Wagner, Rebecca A Burger, Sylvie M Guichard, et al.Journal of Cell Science|December 24, 2013
Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translationClaire L Cope, Rebecca Gilley, Kathryn Balmanno, et al.Breast Cancer Research : BCR|January 25, 2014
Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitroNicola J Jordan, Carol M Dutkowski, Denise Barrow, et al.Cancer Research|June 30, 2001
A virus-directed enzyme prodrug therapy approach to purging neuroblastoma cells from hematopoietic cells using adenovirus encoding rabbit carboxylesterase and CPT-11M M Meck, M Wierdl, L M Wagner, et al.Pageof 11